Miscellaneous (e.g., Hydrocarbons, Etc.) Patents (Class 514/789)
-
Publication number: 20140206776Abstract: Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
-
Publication number: 20140206775Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
-
Publication number: 20140208448Abstract: A novel canola variety designated 43E02 and seed, plants and plant parts thereof, produced by crossing Pioneer Hi-Bred International, Inc. proprietary inbred canola varieties. Methods for producing a canola plant that comprises crossing canola variety 43E02 with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 43E02 through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby. This discovery relates to the canola variety 43E02, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of canola variety 43E02. This discovery further relates to methods for producing canola varieties derived from canola variety 43E02.Type: ApplicationFiled: January 22, 2013Publication date: July 24, 2014Applicant: PIONEER HI-BRED INTERNATIONAL INC.Inventors: Jayantilal Devabhai Patel, Daniel Joseph Stanton, Ferdinand G. Thoonen
-
Publication number: 20140205540Abstract: Methods and compositions for modifying an individual's balance time are disclosed.Type: ApplicationFiled: December 26, 2013Publication date: July 24, 2014Inventor: Alan R. Hirsch
-
Patent number: 8778413Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.Type: GrantFiled: May 12, 2011Date of Patent: July 15, 2014Assignee: Ikaria, Inc.Inventors: Helen H. Usansky, Khurram Jamil
-
Publication number: 20140187652Abstract: Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.Type: ApplicationFiled: March 4, 2014Publication date: July 3, 2014Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Hendrik Heudig, Rosemarie Kientsch-Engel, Sandra Rutz
-
Publication number: 20140179806Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.Type: ApplicationFiled: September 5, 2013Publication date: June 26, 2014Applicant: Fio CorporationInventors: Kevin Kain, W. Conrad Liles, Laura Erdman, Andrea Conroy
-
Publication number: 20140179805Abstract: This invention provides methods of using a sample with multiple analytical components in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of identifying markers of diseases or conditions.Type: ApplicationFiled: June 14, 2013Publication date: June 26, 2014Inventor: Harry Stylli
-
Publication number: 20140179808Abstract: Assays and reagents for the detection of autoantibodies to detect ovarian carcinomas are provided.Type: ApplicationFiled: October 22, 2013Publication date: June 26, 2014Applicant: BIO-RAD LABORATORIES, INC.Inventor: John J. Flanagan
-
Publication number: 20140179807Abstract: The present invention includes an apparatus, system and method for the development and use of transcriptional modules by obtaining individual gene expression levels from cells obtained from one or more patients with a disease or condition; recording the expression value for each gene in a table that is divided into clusters; iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules.Type: ApplicationFiled: October 17, 2013Publication date: June 26, 2014Applicant: Baylor Research InstituteInventors: Damien Chaussabel, Jacques Banchereau
-
Publication number: 20140179809Abstract: The present invention is direct to methods of determining the location of a bacterial load in the lungs of a subject.Type: ApplicationFiled: December 12, 2013Publication date: June 26, 2014Applicant: Avisa Pharma Inc.Inventor: Elizabeth A. Perkett
-
Publication number: 20140171522Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: July 5, 2012Publication date: June 19, 2014Applicant: ASTUTE MEDICAL, INCInventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20140163118Abstract: Described herein are expression signatures of genes and coordinately expressed gene networks associated with skin aging, methods used to determine the physiological age of skin, and methods used to screen for compounds used to reduce the visible signs of aging of the skin.Type: ApplicationFiled: May 3, 2012Publication date: June 12, 2014Applicant: DERMACHIP INC.Inventors: Giammaria Giuliani, Raymond Rodriguez, Somen Nandi
-
Publication number: 20140163119Abstract: Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Inventors: Jared Ordway, Nathan Lakey, Rebecca Maloney, Theresa Rohlfing
-
Publication number: 20140155499Abstract: Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Inventors: James L. Cook, Cristi R. Cook, Aaron M. Stoker, Keiichi Kuroki, Bridget Colleen Garner, Richard Evans, Brandon Lee Roller, Prakash Sidha Jayabalan
-
METHODS AND SYSTEMS FOR MEASURING AND USING THE OXIDATION-REDUCTION POTENTIAL OF A BIOLOGICAL SAMPLE
Publication number: 20140121158Abstract: Methods and systems for measuring and using the oxidation-reduction characteristics of a biological sample are provided. The system generally includes a test strip and a readout device. A fluid sample is placed in the test strip, and the test strip is in turn operatively connected to the readout device. The readout device provides a controlled current that is sent across the fluid in the sample chamber. In addition, the readout device identifies an inflection point or transition time at which the voltage between contacts of the test strip is changing at the highest rate. The oxidation-reduction capacity of the sample is taken as the integral of the current profile from the time at which current begins to be supplied to the sample to the identified transition time.Type: ApplicationFiled: October 23, 2013Publication date: May 1, 2014Applicant: Luoxis Diagnostics, Inc.Inventors: Raphael Bar-Or, David Bar-Or, Leonard T. Rael -
Publication number: 20140121287Abstract: The present invention relates to peptide nucleic acid (PNA) probes, PNA probe sets and methods for the analysis of Gram positive and Gram negative organisms optionally present in a sample. The invention further relates to diagnostic kits comprising such PNA probes.Type: ApplicationFiled: October 1, 2013Publication date: May 1, 2014Inventors: Janeen R. Shepard, Mark Fiandaca, Henrik Stender
-
Publication number: 20140113979Abstract: The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: The Regents of the University of CaliforniaInventors: Ajit Varki, Richard B. Schwab, Vered Padler-Karavani, Nancy Hurtado-Ziola
-
Publication number: 20140113978Abstract: The present invention is directed to methods and products for defining a biomarker of disease phenotype. The present invention further relates to methods and kits for determining a subject's risk of developing recurrent hepatocellular carcinoma based on a defined microRNA biomarker that reliably distinguishes hepatocellular carcinoma disease recurrence from non-recurrence. The invention also relates to methods of treating a patient having heptocellular carcinoma based on their risk of developing hepatocellular carcinoma disease recurrence.Type: ApplicationFiled: May 1, 2012Publication date: April 24, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Christopher Barry, Tony Godfrey, Anthony Almudevar
-
Publication number: 20140088203Abstract: The present invention relates to a method, in particular an in vitro method, for predicting a risk of onset of abdominal obesity in a subject, which method comprises the steps of: a1) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) based on the result of the measurement in step a1), determining a risk of onset of abdominal obesity in the subject.Type: ApplicationFiled: April 2, 2012Publication date: March 27, 2014Applicants: CHU de Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Jacques Amar, Rémy Burcelin
-
Publication number: 20140080925Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: ApplicationFiled: February 7, 2012Publication date: March 20, 2014Applicant: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20140058000Abstract: The present invention relates to a method for predisposition prediction of a subject to the development of cervical cancer and/or cancer precursors in an infection with the human papilloma virus (HPV) and/or for the detection of a persistent HPV infection, the method comprising the steps of obtaining a sample from the subject; and detecting at least one of the diagnostic markers or fragments thereof listed in Table 1 in the sample obtained from the subject.Type: ApplicationFiled: November 4, 2013Publication date: February 27, 2014Applicant: Eberhard-Karls-Universitaet Tuebingen Universitaet UniversitaetsklinikumInventors: Thomas Iftner, Frank Stubenrauch, Anna Manawapat, Susanne Krueger Kjaer
-
Publication number: 20140051773Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20140051774Abstract: An object of the present invention is to provide a method for producing a composition having a disperse phase finely dispersed in a continuous phase with low polydispersity, the method which is excellent in production efficiency This object is achieved by a method for producing a composition having a disperse phase finely dispersed in a continuous phase, the method comprising the steps of: (A) supplying a swirl flow of a continuous phase liquid into a cylinder having a circumferential surface partially or wholly composed of a porous membrane; (B1) jetting a disperse phase fluid through the porous membrane into the swirl flow to form a fluid column extending from a surface of the porous membrane into the cylinder; and (B2) by means of a shear force of the swirl flow, cutting off a part of the fluid column at a position with a distance of 2P to 10P in a radial direction from the surface of the porous membrane, where P is an average pore size of the porous membrane.Type: ApplicationFiled: March 30, 2012Publication date: February 20, 2014Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventor: Mitsuya Shimoda
-
Publication number: 20140024725Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.Type: ApplicationFiled: December 19, 2011Publication date: January 23, 2014Inventors: Jéróme Aubert, Martin Steinhoff
-
Publication number: 20140018448Abstract: The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.Type: ApplicationFiled: March 26, 2012Publication date: January 16, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Rebecca Gonsky, Richard Deem, Stephan R. Targan
-
Publication number: 20140018445Abstract: A method for detection of pathogenic organisms wherein the method includes differentiation between species. The method is especially suitable to detect and to diagnose infection by pathogenic organisms which are hard and/or laborious to detect with conventional methods. The method relies upon analysis of specific variable regions of the RNase P RNA gene, namely the P3 and/or P19 region(s).Type: ApplicationFiled: January 2, 2013Publication date: January 16, 2014Inventors: Björn HERRMANN, Leif KIRSEBOM, Pelle STOLT
-
Publication number: 20140018446Abstract: Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased.Type: ApplicationFiled: July 16, 2013Publication date: January 16, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Donald R. Royall, Raymond F. Palmer
-
Publication number: 20140018447Abstract: The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD).Type: ApplicationFiled: March 26, 2012Publication date: January 16, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dermot P. McGovern, Marla C. Dubinsky, Kent D. Taylor, Stephan R. Targan, Jerome I. Rotter
-
Publication number: 20140011895Abstract: The disclosure provides novel SLE biomarkers. The disclosure further provides kits and methods of diagnosing, prognosing, and stratifying subjects with the disease by utilizing the novel SLE biomarkers.Type: ApplicationFiled: March 6, 2013Publication date: January 9, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: LIFE TECHNOLOGIES CORPORATION
-
Publication number: 20140005281Abstract: Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD. Despite the success of statins, many patients abandon treatment owing to neuromuscular adverse drug reactions (ADRs). Genome-wide association studies have identified the single-nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene as being associated with an increased risk for statin-induced ADRs. By studying slow-channel syndrome transgenic mouse models, this invention determined that statins trigger ADRs in mice expressing the mutant allele of the rs137852808 SNP in the nicotinic acetylcholine receptor (nAChR) ?-subunit gene CHRNA1. Mice expressing this allele show a remarkable contamination of end-plates with caveolin-1 and develop early signs of neuromuscular degeneration upon statin treatment. The invention demonstrates that genes coding for nAChR subunits may contain variants associated with statin-induced ADRs.Type: ApplicationFiled: July 2, 2012Publication date: January 2, 2014Inventors: Jose A. Lasalde, Orestes Quesada, Carlos Baez, Gary Grajales, Walter Silva
-
Publication number: 20140005282Abstract: Specific peptides are provided, and derived ionization characteristics of those peptides, from the Hepatocyte Growth Factor Receptor (cMET) protein. The peptides are particularly and surprisingly advantageous for quantifying by the method of Selected Reaction Monitoring (SRM) mass spectrometry the cMET protein directly in biological samples that have been fixed in formalin, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including: formalin-fixed tissue/cells; formalin-fixed/paraffin embedded (FFPE) tissue/cells; FFPE tissue blocks and cells from those blocks; and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: December 27, 2011Publication date: January 2, 2014Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20130345322Abstract: The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1?, TGF?1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer.Type: ApplicationFiled: July 14, 2011Publication date: December 26, 2013Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Leah Jane Cosgrave, Bruce Tabor, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20130338242Abstract: An apparatus and a method for dispersing particulate materials prone to agglomeration, in a liquid. Particulate materials are exposed to a liquid and put into that liquid to form a suspension or a dispersion in a controlled method thereby minimizing agglomerates. The method uses mechanical/hydro mixing that prevents the physical deterioration of the particulate material and inhibits agglomeration of the particles. In many cases, these materials may be nanomaterials. Almost all particulate materials can be handled in this manner. This method has been found to be especially useful for preparing solutions of exfoliated graphene and certain drugs.Type: ApplicationFiled: September 12, 2012Publication date: December 19, 2013Inventors: Scott Murray, Michael Knox
-
Publication number: 20130338243Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.Type: ApplicationFiled: August 9, 2013Publication date: December 19, 2013Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Alex Kentsis, Hanno Steen, Richard Bachur
-
Publication number: 20130317123Abstract: Large deletions have been identified in the PMS2 gene in patients. The large deletions predispose the patients to Lynch syndrome associated cancers.Type: ApplicationFiled: March 22, 2013Publication date: November 28, 2013Applicant: MYRIAD GENETICS, INC.Inventor: MYRIAD GENETICS, INC.
-
Publication number: 20130317124Abstract: Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described.Type: ApplicationFiled: August 7, 2013Publication date: November 28, 2013Applicant: Orion Genomics LLCInventors: Jared Ordway, Nathan Lakey, Rebecca Maloney, Theresa Rohlfing
-
Publication number: 20130317125Abstract: Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described.Type: ApplicationFiled: August 7, 2013Publication date: November 28, 2013Applicant: Orion Genomics LLCInventors: Jared Ordway, Nathan Lakey, Rebecca Maloney, Theresa Rohlfing
-
Patent number: 8580251Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.Type: GrantFiled: October 19, 2009Date of Patent: November 12, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
-
Publication number: 20130296447Abstract: A method of assessing the risk in female patients of having neurocognitive developmentally disabled children. The method including measuring the toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant. Quantify the risk of neurocognitive developmentally disabled children born to the subject by comparing the toxin concentrations in the subject to reference concentrations utilizing a weighting algorithm. Advise the patient of the quantified risk of having neurocognitive developmentally disabled children. The concentrations of dialkyl phosphates, endocrine disruptors, and xenoestrogens compounds are evaluated. Additionally, the level of PON1 activity may be included in the risk assessment weighting algorithm.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventor: James Alexander Bralley, III
-
Publication number: 20130289142Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 1, 2013Publication date: October 31, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20130289141Abstract: Disclosed are methods and materials for assessing cardiac disease, including cardiac failure, cardiac hypertrophy, thoracic aortic aneurysm, left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum, or in cardiac tissue.Type: ApplicationFiled: November 11, 2011Publication date: October 31, 2013Applicant: Medical University of South CarolinaInventors: Francis G. Spinale, Michael R. Zile, Robert E. Stoud, John S. Ikonomidis, Jeffrey A. Jones
-
Publication number: 20130289139Abstract: The present disclosure relates generally to the field of immunological-based diagnostic assays. Particularly, a method is contemplated herein for measuring cell-mediated immune response reactivity. The present disclosure further provides a method to reduce incidence of non-specific immune response reactivity in a cell-mediated immune response-based assay, comprising contacting a sample with a basic peptide structure capable of binding to lipopolysaccharides, such as polymyxin B or a sushi peptide.Type: ApplicationFiled: May 23, 2011Publication date: October 31, 2013Applicant: CELLESTIS INTERNATIONAL PTY LTD.Inventors: Anthony J. Radford, Emily Manktelow, Jeff Boyle, Jenny Louise Howard
-
Publication number: 20130289140Abstract: A biomarker for Alzheimer's disease (AD) comprising a complex of an A? amyloid peptide and a cell or a cellular membrane. Non-invasive methods for diagnosing Alzheimer's disease or monitoring its development or progression using this biomarker.Type: ApplicationFiled: April 30, 2013Publication date: October 31, 2013Applicants: Centre National de la Recherche Scientifique, Innovative Health DiagnosticsInventors: Corinne MBEBI-LIEGEOIS, Jean De Barry, Francois Sellal
-
Patent number: 8568777Abstract: The present invention relates to packaged orally consumable film dosage units for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an orally consumable film for delivery of the complexate and a package for containing the orally consumable film. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the film, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.Type: GrantFiled: March 30, 2007Date of Patent: October 29, 2013Assignee: MonoSol Rx, LLCInventor: Richard C. Fuisz
-
Publication number: 20130280338Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: ApplicationFiled: April 17, 2013Publication date: October 24, 2013Inventors: Klaus WENING, Lutz BARNSCHEID, Sebastian SCHWIER
-
Publication number: 20130280304Abstract: The present invention provides an improved method of administering a medicinal, dental or nutritional agent to a non-human animal, such as a domesticated dog or cat. The method comprises mixing a liquid composition in a mixer at various speeds and pressures for a period of time; pouring the liquid composition onto a conveyor belt propelled by polymer rollers, wherein the polymer rollers allow the components to advance on the conveyor belt without adhering to the belt; evenly distributing the composition on the belt with the use of a knife; heating the composition in one or more hot-air chambers; obtaining a film comprised of the composition; cutting the film into strips; and then administering one or more of the strips to the non-human animal by placing the strip under the tongue of the animal, i.e., by sub-lingual administration.Type: ApplicationFiled: October 22, 2012Publication date: October 24, 2013Inventor: Douglas Kramer
-
Publication number: 20130267613Abstract: The present invention relates to an assay to perform a molecular determinant-based functional killer immunoglobulin-like receptors (KIR) allele typing and ligand typing. In particular the present invention provides methods, compositions, and kits for a single nucleotide polymorphism (SNP) assay to type various allele groups of KIR2DL1 and KIR ligand with distinct functional properties based on polymorphism at position 245 in KIR2DL1, position 77 in HLA-C, and position 83 in HLA-B and HLA-A. The assays are suitable for use in predicting NK cell activity in health, disease, and transplantation.Type: ApplicationFiled: October 5, 2011Publication date: October 10, 2013Applicant: St Jude Children's Research HospitalInventors: Wing Leung, Rafijul Bari
-
Publication number: 20130261196Abstract: The invention provides mixtures of linear nucleic acid probes, including circularizing “capture” probes, capable of massively multiplex capture of one or more sequences of interest from a plurality of target organisms. The methods provided by the invention enable rapid, precise, and economical detection of one or more organisms of interest, such as common pathogens.Type: ApplicationFiled: June 10, 2011Publication date: October 3, 2013Inventors: Lisa Diamond, Jochen Kumm, Philip Alexander Rolfe
-
Publication number: 20130253471Abstract: Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation of electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: May 21, 2013Publication date: September 26, 2013Applicant: Medtronic Ardian Luxembourg S.a.r.I.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand